Fennec Pharmaceuticals and Norgine Collaborate for the Commercialization of Pedmarqsi in the EU, Australia and New Zealand
Shots:
- Fennec & Norgine have signed an exclusive licensing agreement to commercialize Pedmarqsi in the EU, Australia & New Zealand for preventing hearing loss caused by cisplatin in localized, non-metastatic solid tumors patients (1mos. to <18yrs.)
- Under the agreement, Fennec obtains ~$43.5M up front & ~$228.8M commercial & regulatory milestones plus double-digit net-sales-based tiered royalties while Norgine gains its commercialization rights
- Pedmarqsi was assessed in 2 trials incl. SIOPEL-6 study of hepatoblastoma children (n=114, 19mos.) showing hearing loss in 35% receiving the drug post 6hrs. of cisplatin vs 67% receiving cisplatin & 2nd study of children (n=125, 1mos. to 18yrs.) with multiple cancers showing a hearing loss in 29% vs 56%
Ref: Fennec Pharmaceuticals | Image: Fennec Pharmaceuticals
Related News:- Fennec Pharmaceuticals’ Pedmarqsi (sodium thiosulfate) Receives EC’s Marketing Authorization for Cisplatin-Induced Ototoxicity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
